Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Clin Lab Anal ; 35(8): e23887, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34264524

RESUMO

BACKGROUND: Breast cancer (BC) is the leading cause of cancer death in women worldwide. Most BC studies on candidate microRNAs were tissue specimen based. Recently, there has been a focus on the study of cell-free circulating miRNAs as promising biomarkers in (BC) diagnosis and prognosis. Therefore, we aimed to investigate the circulating levels of miR-10b and its target soluble E- cadherin as potentially easily accessible biomarkers for breast cancer. METHODS: Sixty-one breast cancer patients and forty-eight age- and sex-matched healthy volunteers serving as a control group were enrolled in the present study. Serum samples were used to assess miRNA10b expression by TaqMan miRNA assay technique. In addition, soluble E-cadherin expression level in serum was determined using ELISA technique. RESULT: Circulating miR-10b expression level and serum sE-cadherin was significantly upregulated in patients with BC compared to controls. Moreover, serum miR-10b displayed progressive up-regulation in advanced stages with higher level in metastatic compared to non-metastatic BC. Additionally, the combined use of both serum miR-10b and sE-cadherin revealed the highest sensitivity and specificity for detection of BC metastasis (92.9% and 97.9% respectively) with an area under curve (AUC) of 0.98, 95% CI (0.958-1.00). CONCLUSION: Our data suggest that circulating miR-10b could be utilized as a potential non-invasive serum biomarker for diagnosis and prognosis of breast cancer with better performance to predict BC metastasis achieved on measuring it simultaneously with serum sE-cadherin. Further studies with a large cohort of patients are warranted to validate the serum biomarker for breast cancer management.


Assuntos
Antígenos CD/sangue , Biomarcadores Tumorais/genética , Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Caderinas/sangue , Glicoproteínas de Membrana/sangue , Receptores Imunológicos/sangue , Adulto , Idoso , Biomarcadores Tumorais/sangue , Neoplasias da Mama/sangue , Estudos de Casos e Controles , MicroRNA Circulante , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Glicoproteínas de Membrana/genética , Pessoa de Meia-Idade , Prognóstico , Curva ROC , Receptores Imunológicos/genética , Sensibilidade e Especificidade
2.
Asian Pac J Cancer Prev ; 20(9): 2659-2665, 2019 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-31554361

RESUMO

Background: Cancer breast is the most common malignant tumor in females globally. Mechanisms linking inflammatory cytokines and tumour growth and progression have not been established. Interleukin (IL)-18 has a modifying role in the immune defense against tumor cells. It induces production of IFN-γ. It also increases the immune cells cytotoxic activity and enhances the production of other proinflammatory cytokine. Nitric oxide (NO) has both promoting and inhibiting effects on tumorigenesis. Oxidative stress is a phenomenon that leads to oxidative damage of biomolecules, mutagenesis and carcinogenesis. Objective: The purpose of this research is to identify the potential role of IL18 and NO and their relation to oxidative stress in the development of cancer breast. Patients and Methods: This study included 120 women split into two groups ; control group and patient groups that divided into: group B (30 patients with benign breast tumors), group N (30newly diagnosed cancer breast patients) ; and group M (30 metastatic cancer breast patients). Results: Serum total anti-oxidant capacity was significant high in both cancer breast groups. Total oxidative capacity was significantly higher level in metastatic group. NO levels were significantly higher values in the three cancer breast patients groups compared to control group.IL18 was significantly high in the metastatic group. Conclusions: Serum IL-18 and NO activity can be used as a marker for evaluating disease activity in patients with cancer breast.


Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias da Mama/patologia , Interleucina-18/metabolismo , Óxido Nitroso/metabolismo , Estresse Oxidativo , Neoplasias da Mama/metabolismo , Estudos de Casos e Controles , Progressão da Doença , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica , Oxirredução , Prognóstico , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...